Literature DB >> 29655453

Measuring Clinical Treatment Response in Myasthenia Gravis.

Carolina Barnett1, Laura Herbelin2, Mazen M Dimachkie2, Richard J Barohn2.   

Abstract

In this article we provide an overview of health-related outcome measurement-to better understand what different outcomes used in myasthenia actually measure-and to provide some guidance when choosing measures based on the clinical context and question. In myasthenia, the most commonly used outcome measures are aimed at assessing the signs and symptoms. In this review, we provide a summary of the most commonly used outcome measures. We discuss instruments that gauge disease overall health impact, such as on disability and quality of life. Finally, we discuss other relevant outcomes such as steroid-sparing effects and the role of surrogate markers.
Copyright © 2018 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Disability; Minimal important difference; Myasthenia gravis; Outcome measurement; Responsiveness

Mesh:

Year:  2018        PMID: 29655453      PMCID: PMC6697147          DOI: 10.1016/j.ncl.2018.01.006

Source DB:  PubMed          Journal:  Neurol Clin        ISSN: 0733-8619            Impact factor:   3.806


  13 in total

1.  Social, professional and neuropsychiatric outcomes in patients with myasthenia gravis.

Authors:  Bruno Kusznir Vitturi; Alexandre In Han Kim; Lucas Pari Mitre; Ada Pellegrinelli; Berenice Cataldo Oliveira Valerio
Journal:  Neurol Sci       Date:  2020-06-26       Impact factor: 3.307

2.  Multiple genetic factors affecting the pharmacokinetic and pharmacodynamic processes of tacrolimus in Chinese myasthenia gravis patients.

Authors:  Huan-Yu Meng; Xi Li; Wan-Lin Jin; Cheng-Kai Yan; Xiao-Hua Dong; Qiu Xu; Yu-Yao Peng; Zhi-Bin Li; Yi Li; Zhao-Hui Luo; Li-Qun Xu; Huan Yang
Journal:  Eur J Clin Pharmacol       Date:  2020-01-18       Impact factor: 2.953

Review 3.  Immunoregulatory Cells in Myasthenia Gravis.

Authors:  Ying Wu; Jie Luo; Oliver A Garden
Journal:  Front Neurol       Date:  2020-12-15       Impact factor: 4.003

4.  Patient-Reported Symptom Severity in a Nationwide Myasthenia Gravis Cohort: Cross-sectional Analysis of the Swedish GEMG Study.

Authors:  Malin Petersson; Amalia Feresiadou; Daniel Jons; Andreea Ilinca; Fredrik Lundin; Rune Johansson; Anna Budzianowska; Anna-Karin Roos; Viktor Kågström; Martin Gunnarsson; Peter Sundström; Fredrik Piehl; Susanna Brauner
Journal:  Neurology       Date:  2021-08-10       Impact factor: 9.910

Review 5.  Corticosteroid Treatment-Resistance in Myasthenia Gravis.

Authors:  Henry J Kaminski; Jordan Denk
Journal:  Front Neurol       Date:  2022-04-25       Impact factor: 4.086

6.  Successful Transition from Plasma Exchange to Eculizumab in Acetylcholine Receptor Antibody- and Muscle-Specific Kinase (MuSK) Antibody-Negative Myasthenia Gravis: A Case Report.

Authors:  Gregory T Greenwood; Zachary Lynch
Journal:  Am J Case Rep       Date:  2020-05-17

7.  Respiratory Muscle Training Improves Functional Outcomes and Reduces Fatigue in Patients with Myasthenia Gravis: A Single-Center Hospital-Based Prospective Study.

Authors:  Che-Wei Hsu; Hui-Chen Lin; Wan-Chen Tsai; Yun-Ru Lai; Chih-Cheng Huang; Yu-Jih Su; Ben-Chung Cheng; Mao-Chang Su; Wei-Che Lin; Chia-Ling Chang; Wen-Neng Chang; Meng-Chih Lin; Cheng-Hsien Lu; Nai-Wen Tsai
Journal:  Biomed Res Int       Date:  2020-03-19       Impact factor: 3.411

8.  Disease Severity Assessment and Short-Term Outcome in Patients with Myasthenia Gravis.

Authors:  Deepthi Vemuri; Butchi Raju Garuda; S Gopi; T Sateesh Kumar; U Aruna Kumari
Journal:  Ann Indian Acad Neurol       Date:  2020-02-25       Impact factor: 1.383

9.  Utilization of Decision Tree Algorithms for Supporting the Prediction of Intensive Care Unit Admission of Myasthenia Gravis: A Machine Learning-Based Approach.

Authors:  Che-Cheng Chang; Jiann-Horng Yeh; Hou-Chang Chiu; Yen-Ming Chen; Mao-Jhen Jhou; Tzu-Chi Liu; Chi-Jie Lu
Journal:  J Pers Med       Date:  2022-01-02

10.  Validation of the Italian version of the Myasthenia Gravis Impairment Index (MGII).

Authors:  Francesca Pasqualin; Carolina Barnett; Silvia Vittoria Guidoni; Elisa Albertini; Mario Ermani; Domenico Marco Bonifati
Journal:  Neurol Sci       Date:  2021-09-09       Impact factor: 3.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.